Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Cybin Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cybin wird ein jährliches Gewinn- und Umsatzwachstum von 62.2% bzw. 68.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 57% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -29.5% betragen.

Wichtige Informationen

57.0%

Wachstumsrate der Gewinne

53.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	68.7%
Zukünftige Eigenkapitalrendite	-29.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:CYBN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	117	-19	1	-58	3
3/31/2026	N/A	-84	-74	-70	3
3/31/2025	N/A	-70	-57	-56	3
3/31/2024	N/A	-75	-61	-61	4
12/31/2023	N/A	-70	-60	-59	N/A
9/30/2023	N/A	-51	-45	-44	N/A
6/30/2023	N/A	-49	-50	-47	N/A
3/31/2023	N/A	-47	-51	-47	N/A
12/31/2022	N/A	-52	-50	-46	N/A
9/30/2022	N/A	-58	-52	-48	N/A
6/30/2022	N/A	-66	-48	-47	N/A
3/31/2022	N/A	-68	-46	-45	N/A
12/31/2021	N/A	-63	-43	-42	N/A
9/30/2021	N/A	-58	-38	-38	N/A
6/30/2021	N/A	-43	-27	-26	N/A
3/31/2021	1	-32	-19	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CYBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CYBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CYBN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CYBN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CYBN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CYBN wird voraussichtlich in 3 Jahren unrentabel sein.

Cybin Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2027

Recent updates

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought US$56k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin Inc. to Report Q3, 2022 Results on Feb 10, 2022

Institutional Review Board Grants Approval for Cybin Inc.'s Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for A Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing Covid-Related Distress

Chief Operating Officer recently bought US$97k worth of stock

Cybin Awards Grant for Psychedelic Treatment Clinic At Lenox Hill Hospital to Benefit Underserved Communities

Chief Legal Officer recently bought US$54k worth of stock

Cybin Files Two Additional International Patent Applications in Support of the Company’S Research Phase Programs

Cybin Inc. Deleted from Other OTC

Cybin Files its 13th Patent Application

Cybin Announces Completion of Its 51St Pre-Clinical Psychedelic Molecule Study

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Cybin Inc. Files an International Patent Application Further Strengthening Its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Cybin Inc. Files Its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Cybin Inc. Progresses Two Psychedelic Investigational New Drug Candidates and Announces Completion of its 20th Pre-Clinical Study

Cybin Inc. Announces Executive Changes

Cybin Inc. has completed a Composite Units Offering in the amount of CAD 34.3035 million.

Cybin Inc. Partners with Kernel to Leverage Its Neuroimaging Technology for Psychedelic Therapeutics

Cybin Inc. Provides Update on Patent Filings & Development of Therapeutics Program